Treprostinil not checked
United Therapeutics · UT-15C · UT 15
FollowEvery change as it happens, and a Monday email
Trials
5 active
20 in total · 3 in the EU
Targets
—
None known yet
What this is
- How it works
- Prostacycline Vasodilator FDA class
- How it’s given
- “Parenteral treprostinil will be administered per schedule specified in the arm description.”In the company’s words, NCT05203510 on ClinicalTrials.gov
- Tested for
- Progressive Pulmonary Fibrosis (2 trials), Interstitial Lung Disease (2 trials), Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (2 trials), Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
- Main trialPhase 4
- “The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).”In the company’s words, NCT05203510 on ClinicalTrials.gov
- Other names
- Remodulin · Orenitram · UT-15C · UT 15 · Flolan · Tyvaso
Other drugs for Progressive Pulmonary Fibrosis
- SC1011JOYO Pharma · Phase 2/3
- NerandomilastBoehringer Ingelheim · Phase 3
- NAL ERTrevi Therapeutics · Phase 3
- AdmilparantBristol Myers Squibb · Phase 3
- AK3280Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 3
- TDI01Beijing Tide Pharmaceutical Co., Ltd · Phase 3
Copies tested against it1
Other companies’ versions, mostly cheaper copies for when the patent ends
- C16TRInsmed Incorporated · NCT06193031 · finished
Coming up4
- Nov 2027Phase 3 trial completes · ClinicalTrials.gov
- May 2028Phase 2 trial completes · ClinicalTrials.gov
- Dec 2029Phase 3 trial completes · ClinicalTrials.gov
- Sep 2034Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials20
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Active, not recruiting | 30 Apr 2026 | A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension | |
| Phase 3Recruiting | Nov 2027 | Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | |
| Phase 3Enrolling by invitation | Dec 2029 | Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease | |
| Phase 2/3Not yet recruiting | Sep 2034 | An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) | |
| Phase 2Not yet recruiting | May 2028 | Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) | |
| Phase 4Terminated | Sep 2009 | Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH | |
| Phase 4Terminated | Jan 2010 | Rapid Switch From Flolan to Remodulin in the Outpatient Clinic | |
| Phase 4Completed | 25 Feb 2014 | TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH) | |
| Phase 4Completed | 11 May 2022 | EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension | |
| Phase 3Completed | Oct 2007 | Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH) | |
| Phase 3Completed | 12 Feb 2020 | An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension | |
| Phase 3Terminated | 13 Oct 2022 | A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD) | |
| Phase 3Terminated | 29 Nov 2022 | Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD) | |
| Phase 3Completed | 30 Jun 2025 | Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | |
| Phase 3Completed | 2 Feb 2026 | Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | |
| Phase 2/3Withdrawn | Jun 2010 | Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients | |
| Phase 2/3Completed | 26 Dec 2019 | Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE | |
| Phase 2/3Terminated | 1 Aug 2021 | An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE | |
| Phase 2Completed | 20 Jul 2017 | Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years | |
| Phase 2Terminated | 27 Sep 2022 | Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026